AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05689437 — intervention group
Intervention type: OTHER
Intervention: Routine, automatic presentation of ILD risk level for evaluation by the clinician.
Description: Participating clinicians will be provided with an ILD risk estimate for all lung cancer patients receiving RT who are deemed potentially high-risk based on the model. In these cases, the clinician will receive an email identifying the patient medical record number (MRN) and 'potential high-risk for ILD' flag. Clinicians will then be able to decide whether, based on the information, they want to reassess the patient for ILD prior to starting treatment. Clinicians will also be presented with a short survey each time they are sent an email for a potential high-risk for ILD case so the study team can better understand how that information was used, if at all.
Study NCT05689437 — intervention group
Intervention type: OTHER
Intervention: Application of SGR machine learning model to diagnostic and planning imaging
Description: The SGR machine learning model will be applied to the imaging of lung cancer patients with node negative lung cancer receiving stereotactic RT. The automatic calculation will compare target lesions on the patient's diagnostic images with those same lesions on treatment planning images.
Study NCT05689437 — intervention group
Intervention type: OTHER
Intervention: Routine estimation of tumor specific growth rate (SGR) for lesions being considered for radiation therapy presented to clinician.
Description: Participating clinicians will be provided with an SGR calculation for each lung cancer patient with node negative lung cancer receiving stereotactic RT. This SGR calculation will be presented to clinicians, who will then be able to decide, based on the information, how they want to address and track a patient's overall survival and failure free survival. Clinicians will also be presented with a short survey each time they are provided with a patient's SGR calculation so the study team can better understand how that information was used, if at all.
Study NCT05689437 — intervention group
Intervention type: OTHER
Intervention: Application of CBCT machine learning model to on-treatment imaging
Description: The CBCT machine learning model will be applied to on-treatment imaging as part of routine care for patients with node positive lung cancer receiving standard RT. An indicator of lung density changes will be calculated automatically by comparing cone beam CTs (CBCTs) completed prior to each treatment.
Study NCT05689437 — intervention group
Intervention type: OTHER
Intervention: Routine monitoring of lung density changes during the course of treatment presented to clinician.
Description: Participating clinicians will be provided with a daily indicator of lung density changes for each patient with node positive lung cancer receiving standard RT. This measurement will be presented to the clinical team, who will then be able to decide, based on the information, how they want to address and track relevant outcomes such as pneumonitis. Additionally, this information may provide the clinical team with feedback about the lung reaction occurring as a result of treatment. Density changes will be documented and monitored for future validation studies, which are outside of the scope of this application.
Study NCT05724290 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: EGR2
Description: We investigated the expression of EGR2 in patients with nasal polyps through immunohistochemistry.
Study NCT05937880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leflunomide
Description: When patients appeared with rashes and treated with antibiotics, antihistamines, calcium supplements, and glucocorticoids (2 mg/kg/d) for 5 days. The rashes do not subside or fresh rash still appears, and it frequently repeats more than 3 times during hospitalization. Leflunomide would be administered
Study NCT03555552 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anticoagulation and Thrombosis Point of Care Test(AT-POCT)
Description: Capillary action automatically draws blood into the channel containing printed assay reagents which solubilize upon contact with blood and react with analytes of interest.
Study NCT03555552 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anticoagulation and Thrombosis Point of Care Test(AT-POCT)
Description: Capillary action automatically draws blood into the channel containing printed assay reagents which solubilize upon contact with blood and react with analytes of interest.
Study NCT03555552 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Duke Central Automated Laboratory (DCAL)
Description: DCAL measurement of INR will occur by an ACL TOP 750 Analyzer (IL Inc.), and LDH by standard enzymatic activity assay will be run on the automated Beckman DxC800.
Study NCT03555552 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Duke Central Automated Laboratory (DCAL)
Description: DCAL measurement of INR will occur by an ACL TOP 750 Analyzer (IL Inc.), and LDH by standard enzymatic activity assay will be run on the automated Beckman DxC800.
Study NCT06351176 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical tests
Description: The investigators perform the following clinical tests: vibration threshold test, monofilament test, and height, weight and waist circumference measurement in every participant.
Study NCT06351176 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Biochemical tests
Description: The investigators perform blood and urine tests in every participant.
Study NCT06351176 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: DXA scan with TBS and VFA
Description: The investigators perform a dual energy x-ray absorptiometry (DXA scan or osteodensitometry) including trabecular bone score (TBS) and Vertebral Fracture Assessment (VFA) in every participant.
Study NCT06351176 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: AGEReader
Description: The investigators perform a skin advanced glycation end products (AGEs) measurement with the AGE Reader machine in every participant.
Study NCT06551740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HUC2-344
Description: per oral
Study NCT06551740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HUC2-344-R1, HUC2-344-R2
Description: per oral
Study NCT04772443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWJ1506
Description: DWJ1506
Study NCT04772443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWJ1507
Description: DWJ1507
Study NCT04772443 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DWC202011
Description: DWC202011
Study NCT04772443 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DWJ1177
Description: DWC202011
Study NCT05277207 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Smoking Cessation Facilitation Meetings
Description: Participants will participate in 5-7 meetings in which they will receive cognitive-behavioral therapy for tobacco cessation.
Study NCT05277207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Personalized Smoking Cessation Pharmacotherapy
Description: Participants may receive pharmacotherapy for smoking cessation based on VA Pharmacy Benefits Management Services guidelines. Medications may include nicotine-replacement therapy, varenicline, and/or bupropion.
Study NCT05277207 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Text Messaging Support
Description: If the participant has a working cell phone and is willing to receive text messages, supportive, personalized text messages will be sent to the participant starting after Session 1 and extending through 6 months post-quit using VA's Annie texting capability.
Study NCT05277207 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SmokefreeVET
Description: Participants will receive a referral to SmokefreeVET, a text-messaging intervention designed to help veterans prepare for and attempt quitting smoking.
Study NCT05277207 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: VA Quitline
Description: Participants will receive a referral to VA Quitline, which is a nationally available telehealth intervention that provides assistance to veterans who wish to quit tobacco use. Quitline includes five sessions of cognitive-behavioral treatment.
Study NCT05277207 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education about pharmacotherapy
Description: Participants will receive a handout that provides them with information about pharmacotherapies for tobacco cessation.
Study NCT04900311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pyrotinib + trastuzumab + nab-paclitaxel
Description: patients will be treated every 3 weeks for four cycles prior to surgery at following doses: pyrotinib: 400 mg/day, orally, qd trastuzumab: IV infusion on Day 1 every 3 weeks with loading dose of 8 mg/kg in Cycle 1, and 6 mg/kg in Cycles 2-4 nab-paclitaxel: 260 mg/m2 IV infusion on Day 1 every 3 weeks, or 125 mg/m2 IV infusion on Days 1, 8 and 15 every 3 weeks (the nab-paclitaxel administration cycle was determined by investigator at each site)
Study NCT04900311 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pertuzumab + trastuzumab + nab-paclitaxel
Description: patients will be treated every 3 weeks for four cycles prior to surgery at following doses: pertuzumab: IV infusion on Day 1 every 3 weeks with loading dose of 840 mg for Cycle 1, followed by 420 mg for Cycles 2-4 trastuzumab: IV infusion on Day 1 every 3 weeks with loading dose of 8 mg/kg in Cycle 1, and 6 mg/kg in Cycles 2-4 nab-paclitaxel: 260 mg/m2 IV infusion on Day 1 every 3 weeks, or 125 mg/m2 IV infusion on Days 1, 8 and 15 every 3 weeks (the nab-paclitaxel administration cycle was determined by investigator at each site)
Study NCT05342571 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral, Psychological or Informational Intervention
Description: Participate in ABC session
Study NCT05342571 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT05342571 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Medical records reviewed
Study NCT05342571 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Receive patient guidebook
Study NCT05342571 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Complete surveys
Study NCT05412134 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pro2 - 75% of participant's MIP
Description: Each participant will be provided a PrO2™ device and trained on its use as well as its accompanying PrO2 Fit™ app. The PrO2™ is a flow-resistive device that provides inspiratory resistance via a fixed 2mm orifice and has Bluetooth connectivity to most IOS/Android devices or Mac/Windows computers. The PrO2™ device and app allows for both 100% adherence monitoring and immediate user biofeedback.~Participants will be instructed to inspire forcefully through PrO2™ until the device signals that the user has achieved the target resistance (via audible alarm and visible light signal). The research team will implement biofeedback signals at a specific inspiratory resistance to provide precise and individualized training target. Successful IMR repetitions will require that subjects achieve a pressure target that is 75% of their MIP.
Study NCT05412134 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pro2 - 15% of participant's MIP
Description: Participants in the control intervention will also use the same PrO2™ device but at a reduced peak resistance of 15% MIP. The research team will implement biofeedback signals at a specific inspiratory resistance to provide precise and individualized training target. Successful IMR repetitions will require that subjects achieve a pressure target that is 15% of their MIP for each repetition. Participants will perform 3 sets of 50 inspiratory breaths 3 times per week.
Study NCT06170710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 monoclonal antibody
Description: Postoperative CCRT followed by any anti-PD-1 monoclonal antibody of the following:~Pembrolizumab, 200mg, Q3W or Nivolumab, 3mg/kg, Q2W or Tislelizumab，200mg，Q3W or Camrelizumab，200mg，Q3W or Sintilimab，200mg，Q3W or Toripalimab，240mg，Q3W
Study NCT06170710 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative CCRT
Description: Postoperative chemoradiotherapy
Study NCT06170710 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postoperative CCRT
Description: Postoperative chemoradiotherapy
Study NCT02502370 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: observation alone
Study NCT02502370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LV5FU2
Study NCT02502370 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LV5FU2
Study NCT02502370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX
Study NCT05817123 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: Administration of the following questionnaires:~* Mutuality scale~* Pittsburgh Sleep Quality Index (PSQI)~* Epworth Sleep Scale (ESS)~* Sleep Condition Indicator (SCI)~* International Physical Activity Questionaire (IPAQ)~* Mediterranean diet score (MDS)~* Quality of Life SF 12~* Hospital Anxiety and Depression Scale (HADS)
Study NCT06401291 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Transcutaneous Electrical Nerve Stimulation
Description: Device consists of two electrodes that are applied to the chest region and are connected to a battery operated TENS (Frequency 80Hz, pulse width 150us and amplitude variable (patient dependent)). The device will be used a minimum of three times daily for 30 minutes and additionally during symptoms.
Study NCT04793945 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: topical steroid and 308nm-Excimer light therapy
Description: applying topical steroid in combination with 308nm-Excimer light therapy to treat Alopecia Areata
Study NCT06104397 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Written exercise guidance by neurologist
Description: Neurologists will provide written exercise education and guidance to their patients with Parkinson's Disease during neurologist visits and/or in after visit summary in the patient's EMR patient portal. The research team will facilitate the development of the written exercise guidance with input and feedback from each site's neurology, clinical, and administrative teams.
Study NCT06104397 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy
Description: A consultative model of physical therapy - a lower dose of physical therapy focused on physical activity and exercise promotion and coaching - will be implemented into each site. In the consultative model of physical therapy, visits are scheduled around needs of the patient, however will involve 1-4 additional visits within 3 months of evaluation and is based on personal factors that influence their exercise prognosis such as self-efficacy, readiness to change, fitness level, age, health literacy, comorbidities, and Parkinson's Disease-related motor and non-motor impairments.
Study NCT06372535 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi Chuan （dose 1）
Description: Participants would take 24-form simplified Tai Chi Chuan 0.5 hour/session, 5 sessions/week for 8 weeks.~There were 10 minutes warm-up, 30 minutes Tai Chi Chuan lesson and 10 minutes cool-down exercises in the Tai Chi Chuan training.
Study NCT06372535 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi Chuan （dose 2）
Description: Participants would take 24-form simplified Tai Chi Chuan 0.5 hour/session, 5 sessions/week for 16 weeks.~There were 10 minutes warm-up, 30 minutes Tai Chi Chuan lesson and 10 minutes cool-down exercises in the Tai Chi Chuan training.
Study NCT06372535 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi Chuan （dose 3）
Description: Participants would take 24-form simplified Tai Chi Chuan 0.5 hour/session, 5 sessions/week for 24 weeks.~There were 10 minutes warm-up, 30 minutes Tai Chi Chuan lesson and 10 minutes cool-down exercises in the Tai Chi Chuan training.
Study NCT06372535 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi Chuan （dose 4）
Description: Participants would take 24-form simplified Tai Chi Chuan 1 hour/session, 5 sessions/week for 8 weeks.~There were 10 minutes warm-up, 60 minutes Tai Chi Chuan lesson and 10 minutes cool-down exercises in the Tai Chi Chuan training.
Study NCT06372535 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi Chuan （dose 5）
Description: Participants would take 24-form simplified Tai Chi Chuan 1 hour/session, 5 sessions/week for 16 weeks.~There were 10 minutes warm-up, 60 minutes Tai Chi Chuan lesson and 10 minutes cool-down exercises in the Tai Chi Chuan training.
Study NCT06372535 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi Chuan （dose 6）
Description: Participants would take 24-form simplified Tai Chi Chuan 1 hour/session, 5 sessions/week for 24 weeks.~There were 10 minutes warm-up, 60 minutes Tai Chi Chuan lesson and 10 minutes cool-down exercises in the Tai Chi Chuan training.
Study NCT06372535 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi Chuan （dose 7）
Description: Participants would take 24-form simplified Tai Chi Chuan 1.5 hour/session, 5 sessions/week for 8 weeks.~There were 10 minutes warm-up, 90 minutes Tai Chi Chuan lesson and 10 minutes cool-down exercises in the Tai Chi Chuan training.
Study NCT06372535 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi Chuan （dose 8）
Description: Participants would take 24-form simplified Tai Chi Chuan 1.5 hour/session, 5 sessions/week for 16 weeks.~There were 10 minutes warm-up, 90 minutes Tai Chi Chuan lesson and 10 minutes cool-down exercises in the Tai Chi Chuan training.
Study NCT06372535 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi Chuan （dose 9）
Description: Participants would take 24-form simplified Tai Chi Chuan 1.5 hour/session, 5 sessions/week for 24 weeks.~There were 10 minutes warm-up, 90 minutes Tai Chi Chuan lesson and 10 minutes cool-down exercises in the Tai Chi Chuan training.
Study NCT06039163 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HH-120
Description: Participants randomized to active treatment in escalation phase will receive HH-120 administered via inhalation for 5 consecutive days (Day 1 to Day 5). Planned dose levels to be used for the escalation phase of the study are 50 (BID), 50 (TID), and 100 (BID) mg. The expansion phase will begin once the recommended dose for expansion phase determined, based on safety and preliminary efficacy data from the escalation phase.
Study NCT06039163 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Participants randomized to placebo group in escalation and expansion phase will receive placebo administered via inhalation for 5 consecutive days (Day 1 to Day 5).
Study NCT05291507 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Muse MRgFUS System
Description: The intended use of the device is to thermally ablate breast tissue under magnetic resonance image guidance. The thermal ablation is performed non-invasively using extracorporeal focused ultrasound.
Study NCT04976127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talineuren
Description: Talineuren is a liposomal formulation of the GM1 Ganglioside for intravenous administration
Study NCT04632121 — intervention group
Intervention type: DRUG
Intervention: Nicorandil 20 MG
Description: Nicorandil is a nicotinamide ester that dilates peripheral and coronary resistance vessels via action on ATP-sensitive potassium channels and possesses a nitrate moiety that promotes systemic venous and coronary vasodilation. As a result of these dual actions, nicorandil reduces preload and afterload and results in an increase in coronary blood flow. In addition to these effects, nicorandil may have cardioprotective actions mediated through the activation of potassium channel
Study NCT05378503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qsymia 3.75Mg-23Mg Extended Release Capsule
Description: From W0 to W2, once a daily.
Study NCT05378503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qsymia 7.5Mg-46Mg Extended Release Capsule
Description: 1. From W2 to W14, once a daily.~2. At W14, if the weight loss rate is 3% or more, from W14 to W56(the end of visit), once a daily.
Study NCT05378503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qsymia 11.25Mg-69Mg Extended Release Capsule
Description: At W14, if the weight loss rate is NOT 3% or more, from W14 to W16, once a daily.
Study NCT05378503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qsymia 15Mg-92Mg Extended Release Capsule
Description: At W14, if the weight loss rate is NOT 3% or more, from W16 to W56(the end of visit), once a daily.
Study NCT05378503 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: From W0(Randomisation) to W56(the End of visit) once a daily.
Study NCT05002803 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Otago Exercise Program
Description: A Home-based Exercise Program to improve strength and balance and prevent falls.
Study NCT05741697 — intervention group
Intervention type: DRUG
Intervention: bi-level ventillation
Description: non-invasive mechanical ventilation
Study NCT06328088 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Non vegetarian
Description: Non vegetarian diet plus supportive treatment including lactulose and/or rifaximin
Study NCT04934358 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical and motivational follow-up treatment
Description: Physical and motivational follow-up treatment
Study NCT04934358 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual rehabilitation program
Study NCT06099535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNK01001 Dose A
Description: Capsules taken orally
Study NCT06099535 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LNK01001 Dose A
Description: Capsules taken orally